Evaluation of Biosimilar Trastuzumab MYL-1401O in HER2-Positive Breast Cancer AJMC, 14 Sep 2022 The authors evaluate the effect and safety of biosimilar trastuzumab MYL-1401O in human epidermal growth factor receptor 2 (HER2…